Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

@article{Bonner2006RadiotherapyPC,
  title={Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.},
  author={James A Bonner and Paul M. Harari and Jordi Giralt and Nozar Azarnia and Dong M Shin and Roger B. Cohen and Christopher Uwe Jones and Ranjan K Sur and David Raben and Jacek Jassem and Roger Ove and Merrill S. Kies and Jos{\'e} Baselga and Hagop Youssoufian and Nadia Amellal and Eric K. Rowinsky and Kian K. Ang},
  journal={The New England journal of medicine},
  year={2006},
  volume={354 6},
  pages={
          567-78
        }
}
BACKGROUND We conducted a multinational, randomized study to compare radiotherapy alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal growth factor receptor, in the treatment of locoregionally advanced squamous-cell carcinoma of the head and neck. [...] Key MethodMETHODS Patients with locoregionally advanced head and neck cancer were randomly assigned to treatment with high-dose radiotherapy alone (213 patients) or high-dose radiotherapy plus weekly cetuximab (211 patients) at…Expand
Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials
TLDR
Cetuximab seems not to provide the most benefit for patients with oropharyngeal cancers but will in patients with T4 tumors, however, the median duration of local control was less as described in the clinical trials. Expand
Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck.
TLDR
The results suggested that cetuximab plus radiotherapy was cost-effective compared with radiotherapy alone under a broad range of different assumptions on the basis of a cost-effectiveness threshold of 20,000 pounds. Expand
Phase II Study of Cetuximab Plus Concomitant Boost Radiotherapy in Japanese Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
TLDR
Tolerability and efficacy were in line with those reported in the Phase III Bonner trial in a Western population of patients with locally advanced squamous cell carcinoma of the head and neck. Expand
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
TLDR
Erlotinib did not increase the toxicity of cisplatin and radiotherapy in patients with locally advanced HNSCC but failed to significantly increase CRR or PFS. Expand
Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.
TLDR
CTX concomitant to RT lowered compliance and increased acute toxicity rates, and these results raise the issue of appropriately selecting patients with head and neck cancer who can benefit from CTX in combination with RT. Expand
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
TLDR
Overall survival was significantly improved in those who experienced an acneiform rash of at least grade 2 severity compared with patients with no rash or grade 1 rash, confirming cetuximab plus radiotherapy as an important treatment option in this group of patients. Expand
Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients
TLDR
BRT using cetuximab for Japanese patients with SCCHN was feasible as an alternative for cisplatin-based concurrent chemoradiation, although longer follow-up is necessary to evaluate late toxicities. Expand
Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.
TLDR
Based on informal comparisons, cetuximab plus radiotherapy appears to be at least as effective as chemoradiotherapy and, moreover, less toxic; however, formal comparisons of these regimens are required before their relative efficacy and tolerability can be conclusively determined. Expand
Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.
  • P. Harari, Jonathan Harris, +10 authors K. Ang
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
TLDR
The delivery of postoperative chemoradiotherapy and cetuximab to patients with SCCHN is feasible and tolerated with predictable toxicity and the docetaxel regimen shows favorable outcome with improved DFS and OS relative to historical controls and has commenced formal testing in a phase II/III trial. Expand
Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?
TLDR
The question of the degree to which adding cetuximab improves the efficacy of radiotherapy in locally advanced SCCHN is explored and how the benefits of cetUXimab plus radiotherapy compare with those achievable with CRT is explored. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 59 REFERENCES
Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study.
  • F. Lewin, L. Damber, +14 authors U. Ringborg
  • Medicine
  • Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 1997
TLDR
No statistically significant benefit in survival was observed for patients treated with neoadjuvant chemotherapy followed by radiotherapy, nor was there any impact of chemotherapy on the number of patients achieving loco-regional tumor control after primary treatment. Expand
Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.
TLDR
The statistically significant improvement in overall survival that was obtained supports the use of concomitant chemotherapy as an adjunct to radiotherapy in the management of carcinoma of the oropharynx. Expand
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
TLDR
Combined treatment for advanced head and neck cancer is more efficacious and not more toxic than hyperfractionated irradiation alone. Expand
Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.
  • F. Denis, P. Garaud, +7 authors G. Calais
  • Mathematics, Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Concomitant radiochemotherapy improved overall survival and locoregional control rates and does not statistically increase severe late morbidity. Expand
Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
TLDR
This aggressive regimen of AFRT with concurrent cisplatin and fluorouracil with or without neck dissection is feasible in the community setting for patients with Stage III and IVA head-and-neck cancer. Expand
Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.
TLDR
Concomitant CT offered improved disease control and survival in advanced head and neck cancer patients due to increased acute toxicity, more supportive care is demanded when CT is given simultaneously. Expand
Update on chemoradiotherapy for head and neck cancer
TLDR
Given the toxicity of concurrent chemoradiotherapy, careful selection of patients is critical and many issues remain to be addressed in future trials, including the optimal chemotherapy regimen, the use of altered fractionation radiotherapy, and the role of induction chemotherapy. Expand
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
  • J. Baselga, J. Trigo, +7 authors A. Eckardt
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
The combination of cetuximab and platinum chemotherapy is an active and well-tolerated approach to the treatment of this poor-prognosis patient population with platinum-refractory recurrent or metastatic SCCHN for whom there are no recommended standard therapeutic options. Expand
Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.
  • F. Robert, M. Ezekiel, +9 authors H. Waksal
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
The most commonly reported adverse events were fever, asthenia, transaminase elevation, nausea, and skin toxicities (grade 1 to 2 in most patients). Expand
Concomitant radiochemotherapy or accelerated radiotherapy: analysis of two randomized trials of the French Head and Neck Cancer Group (GORTEC).
TLDR
It is concluded that both concomitant RT-CT and accelerated RT improved tumor control rates, as compared to conventional RT, along with increased but manageable toxicity. Expand
...
1
2
3
4
5
...